EstefanÃ-a Cerro Herreros

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10194401/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy. Molecular Therapy - Nucleic Acids, 2020, 21, 837-849.	5.1	25
2	rbFOX1/MBNL1 competition for CCUG RNA repeats bindingÂcontributes to myotonic dystrophy typeÂ1/typeÂ2 differences. Nature Communications, 2018, 9, 2009.	12.8	61
3	miR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models. Nature Communications, 2018, 9, 2482.	12.8	60
4	RNA-mediated therapies in myotonic dystrophy. Drug Discovery Today, 2018, 23, 2013-2022.	6.4	37
5	Expanded CCUG repeat RNA expression in Drosophila heart and muscle trigger Myotonic Dystrophy type 1-like phenotypes and activate autophagocytosis genes. Scientific Reports, 2017, 7, 2843.	3.3	12
6	Derepressing muscleblind expression by miRNA sponges ameliorates myotonic dystrophy-like phenotypes in Drosophila. Scientific Reports, 2016, 6, 36230.	3.3	33
7	Increased autophagy and apoptosis contribute to muscle atrophy in a myotonic dystrophy type 1 <i>Drosophila</i> model. DMM Disease Models and Mechanisms, 2015, 8, 679-690.	2.4	74
8	Two Enhancers Control Transcription of Drosophila muscleblind in the Embryonic Somatic Musculature and in the Central Nervous System. PLoS ONE, 2014, 9, e93125.	2.5	13